Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas

Trial Profile

Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Jan 2018

At a glance

  • Drugs Olaparib (Primary) ; Busulfan; Dexamethasone; Filgrastim; Gemcitabine; Glutamine; Melphalan; Palifermin; Pyridoxine; Pyridoxine; Rituximab; Vorinostat
  • Indications Diffuse large B cell lymphoma; Hodgkin's disease; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Jan 2018 Planned End Date changed from 1 Nov 2021 to 1 Apr 2022.
    • 12 Jan 2018 Planned primary completion date changed from 1 Nov 2021 to 1 Apr 2022.
    • 12 Jan 2018 Planned initiation date changed from 1 Nov 2017 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top